Postpartum maternal and infant haematological effects of antenatal second trimester ferric carboxymaltose versus standard-of-care oral iron in Malawi: longitudinal follow-up of a randomised controlled trial
The dataset contains de-identified data of 793 pregnant women and their neonates from Southern Malawi, who were randomised in the REVAMP (RandomisEd trial of intraVenous iron for Anaemia in Malawian Pregnant women) trial and consented to REVAMP EXTENDED. This trial aimed to explore the effect of a single dose of a modern IV iron formulation (ferric carboxymaltose) compared to standard-of-care (oral iron) for anaemia treatment in Malawian pregnant women and their neonates up to 12-months post-partum.
This project contains three separate datasets and corresponding data dictionaries which underlie the variables used in the analysis of the main manuscript. These consist of:
- Baseline characteristics
- Maternal efficacy
- Neonate efficacy
To maintain the privacy and confidentiality of the research participants, access is provided to de-identified data only. Certain variables have not been included due to their risk of re-identification, as outlined in the data dictionaries. These variables are available by the corresponding author (Sant-Rayn Pasricha: pasricha.s@wehi.edu.au) upon reasonable request. For reference, participant record identifiers for both the mothers and neonates were derived independently to reduce the risk of re-identification and therefore cannot be used to link the maternal and neonate data together.
Bill and Melinda Gates Foundation